Atom Investors LP raised its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 1,521.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,088 shares of the conglomerate's stock after purchasing an additional 12,281 shares during the period. Atom Investors LP's holdings in Danaher were worth $3,639,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors have also modified their holdings of DHR. nVerses Capital LLC bought a new stake in Danaher in the second quarter worth $25,000. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher in the 2nd quarter worth about $25,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Danaher during the 3rd quarter worth about $39,000. MidAtlantic Capital Management Inc. bought a new position in Danaher during the 3rd quarter valued at about $40,000. Finally, FSA Wealth Management LLC purchased a new stake in Danaher in the 3rd quarter worth about $50,000. 79.05% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
DHR has been the subject of several recent analyst reports. Barclays cut their target price on Danaher from $285.00 to $275.00 and set an "equal weight" rating on the stock in a research note on Wednesday, October 23rd. TD Cowen increased their target price on Danaher from $310.00 to $315.00 and gave the stock a "buy" rating in a research note on Wednesday, October 23rd. Royal Bank of Canada lowered their target price on shares of Danaher from $333.00 to $311.00 and set an "outperform" rating for the company in a research note on Wednesday, October 23rd. Stephens reaffirmed an "overweight" rating and issued a $315.00 price target on shares of Danaher in a research note on Wednesday, October 23rd. Finally, Stifel Nicolaus boosted their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a "hold" rating in a research report on Wednesday, October 23rd. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Danaher currently has a consensus rating of "Moderate Buy" and a consensus price target of $287.16.
Check Out Our Latest Analysis on Danaher
Danaher Stock Up 0.7 %
Danaher stock traded up $1.60 during trading hours on Monday, reaching $241.29. The stock had a trading volume of 2,513,027 shares, compared to its average volume of 2,760,205. The company has a market cap of $174.28 billion, a price-to-earnings ratio of 46.04, a PEG ratio of 4.41 and a beta of 0.85. The business's 50 day moving average price is $254.59 and its 200-day moving average price is $259.41. Danaher Co. has a 52 week low of $215.68 and a 52 week high of $281.70. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01.
Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the company earned $2.02 earnings per share. The business's revenue for the quarter was up 3.1% on a year-over-year basis. Sell-side analysts anticipate that Danaher Co. will post 7.5 EPS for the current year.
Danaher Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher's dividend payout ratio (DPR) is currently 20.61%.
About Danaher
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
